Phase II study of VcR-CVAD [bortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, dexamethasone] with rituximab consolidation and maintenance for untreated mantle cell lymphoma
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 12 May 2016 Status changed from active, no longer recruiting to completed.
- 16 Jun 2015 Planned End Date changed from 1 Nov 2013 to 1 Aug 2015.
- 19 Jan 2008 New trial record.